LOGIN
ID
PW
MemberShip
2025-10-25 13:51
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
NOVARTIS 2018 Annualreport
NOVARTIS 2018 Annualreport
Input Time : 2019-12-23
[Download file]
go back
OPINION
[Reporter's View] Transparent info, the key to vaccine trust
Reporter's view |
Son, Hyung Min
[Op-Ed] Patients, no time left for 'new drug comb therapies'
Special Contribution |
Eo, Yun-Ho
[Desk¡¯s View] Lift botulinum toxin¡¯s core tech designation
Desk's view |
Lee, Seok-Jun
INTERVIEW
"GI Innovation challenges melanoma"
"...overcoming resistance to PD-1 antibodies" says Myoung Ho Jang, CEO of GI Innovation
"New landscape in DLBCL trt¡¦Columvi¡¤Polivy's bigger role"
Professor Gareth Gregory of Monash University in Australia
"Gilead-Kite will lead the trt landscape for DLBCL in KOR"
Diego Santoro, Head of the International Region for Kite Pharma
Dong-A ST launches Sterlara biosimilar Imuldosa in the US
V-olet challenges to become a blockbuster fat-destroying inj
Kim Seul-ki, PM of Daewoong Pharmaceutical's Nabota Business Team
Data
Roche 2018 Annualreport
Roche 2018 Annualreport
NOVARTIS 2018 Annualreport
NOVARTIS 2018 Annualreport
2018 Multinational Pharma Sales
2018 Multinational Pharma Sales
MOST READ
1
'Distrust in MFDS rises after Leqembi safety issue'
2
Parliamentary inspection of the MFDS to highlight
3
"GI Innovation challenges melanoma"
4
MOHW to institutionalize a fast-track listing system
5
Enhertu redefines the standard in early-stage breast cancer
6
'Rezurock' for cGVHD enters NHIS drug price negotiation
7
Pluvicto demonstrates first-line efficacy in prostate cancer
8
NA presses for reimb of Vyloy, Imjudo, Yescarta
9
Targeting EZH1¡¤2¡¦Hanmi unveils next-gen anticancer agent
10
FutureChem to apply for cond approval of Ludotadipep in KOR